Clinical Trial Detail

NCT ID NCT02440425
Title Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

ovarian carcinoma

peritoneal carcinoma

fallopian tube carcinoma

Therapies

Paclitaxel

Pembrolizumab

Age Groups: adult

No variant requirements are available.